Acelyrin (SLRN) Projected to Post Quarterly Earnings on Thursday

Acelyrin (NASDAQ:SLRN) is expected to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Acelyrin to post earnings of ($0.84) per share for the quarter.

Acelyrin (NASDAQ:SLRN) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.07. On average, analysts expect Acelyrin to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acelyrin Stock Performance

Shares of SLRN stock opened at $2.79 on Thursday. The stock’s 50 day simple moving average is $2.26 and its 200 day simple moving average is $3.84. The company has a market capitalization of $279.91 million, a price-to-earnings ratio of -1.13 and a beta of 1.25. Acelyrin has a twelve month low of $1.85 and a twelve month high of $8.59.

Insider Activity

In other news, CEO Mina Kim sold 17,986 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $2.74, for a total transaction of $49,281.64. Following the transaction, the chief executive officer now owns 671,753 shares of the company’s stock, valued at $1,840,603.22. This represents a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 13.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

SLRN has been the topic of several recent analyst reports. Wells Fargo & Company dropped their price target on Acelyrin from $15.00 to $13.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Citigroup decreased their price target on Acelyrin from $6.00 to $3.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 7th. Finally, HC Wainwright decreased their price target on Acelyrin from $8.00 to $6.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $9.60.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.